Combined intravenous methotrexate and cyclophosphamide for refractory childhood lupus nephritis.
D001798:Blood Proteins / Q000032:analysis; D002908:Chronic Disease; D003176:Complement C3 / Q000032:analysis; D003404:Creatinine / Q000097:blood; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007970:Leukopenia / Q000139:chemically induced; D008181:Lupus Nephritis / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D008727:Methotrexate / Q000009:adverse effects / Q000627:therapeutic use*; D011241:Prednisone / Q000627:therapeutic use; D012709:Serum Albumin / Q000032:analysis
D001798:Blood Proteins; D003176:Complement C3; D007166:Immunosuppressive Agents; D012709:Serum Albumin; D003520:Cyclophosphamide; D003404:Creatinine; D011241:Prednisone; D008727:Methotrexate